The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma

Pathology and Oncology Research- Netherlands

doi 10.1007/s12253-013-9667-4

Full Text

Abstract

Available in

Date

July 14, 2013

Authors

Kamila Wojas-Krawczyk

Publisher

Springer Science and Business Media LLC

Related search

P1.01-43 Next-Generation Sequencing in the Exploration of Genetic Heterogeneity for Lung Adenocarcinoma Patients With EGFR Activating Mutations

Journal of Thoracic Oncology

English

Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations

Experimental and Therapeutic Medicine

English

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

Clinical Cancer Research

Cancer Research

Oncology

2011

English

CT Imaging-Based Histogram Features for Prediction of EGFR Mutation Status of Bone Metastases in Patients With Primary Lung Adenocarcinoma

Cancer Imaging

Nuclear Medicine

Radiology

Ultrasound Technology

English

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

English

EGFR Inhibitors in Treatment of Lung Adenocarcinoma

Research in Oncology

2014

English

P001 Discrepancy of Oncogenic Mutations in Bone Metastasis Derived From Lung Adenocarcinoma

Journal of Thoracic Oncology

English

Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation

Journal of Thoracic Oncology

English

Can We Omit Radiotherapy in Case of Brain Metastases for Patients With Mutant EGFR Lung Adenocarcinoma?

Translational Lung Cancer Research

Oncology

2017

English

Amanote Research

The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma

Pathology and Oncology Research- Netherlands

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

P1.01-43 Next-Generation Sequencing in the Exploration of Genetic Heterogeneity for Lung Adenocarcinoma Patients With EGFR Activating Mutations

Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

CT Imaging-Based Histogram Features for Prediction of EGFR Mutation Status of Bone Metastases in Patients With Primary Lung Adenocarcinoma

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

EGFR Inhibitors in Treatment of Lung Adenocarcinoma

P001 Discrepancy of Oncogenic Mutations in Bone Metastasis Derived From Lung Adenocarcinoma

Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation

Can We Omit Radiotherapy in Case of Brain Metastases for Patients With Mutant EGFR Lung Adenocarcinoma?